CD8A and cancer: The most important reason we think is that, compared with GZMH, NKG7 is closer to CD8+ T cells, as a number of reports have indicated that NKG7 is required for CD8+ T immune activity in antitumor cytotoxicity, cancer immunotherapy, and anti‐inflammation [34, 35, 36].